secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001628280-25-025573
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera gets Health Canada nod for Phase 1 trial of ABCL635 for hot flashes
-----------------------------------------------------------------------------

- Received No Objection Letter from Health Canada for ABCL635, an NK3R antagonist for non-hormonal treatment of vasomotor symptoms.
- Phase 1 trial to evaluate safety, PK, and PD in healthy participants and postmenopausal women with moderate-to-severe VMS.
- Trial expected to begin in Q3 2025.
- ABCL635 is an investigational antibody antagonist targeting NK3R, developed for hot flashes due to menopause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/0001628280-25-025573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/abcl-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-025573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer